Breast cancer's complexity, based on receptor profiles and clinical traits, poses a challenge to researchers and clinicians. Customized medicines, like Herceptin and Perjeta, have essentially promoted outcomes for HER2-positive breast cancer patients, minimizing side effects and enhancing their quality of life. This evidence concerns the gene ERBB2 and breast carcinoma.